Quick Answer: Beyond the commonly discussed vitamins and minerals (D, B12, magnesium, CoQ10), medications can deplete dozens of lesser-known but critical nutrients — including carnitine, taurine, glutathione, choline, inositol, alpha-lipoic acid, selenium, chromium, and essential amino acids. This guide covers 30 nutrients not in our main depletion database, identifying which drug classes deplete each one, the mechanisms involved, clinical significance, and evidence-based repletion protocols.
Our Complete Medication-Nutrient Depletion Database covers the nutrients that most healthcare providers know about: the B vitamins, vitamin D, magnesium, calcium, potassium, CoQ10, iron, and zinc. These are the nutrient depletions that make it into pharmacy reference books and drug interaction databases.
But human metabolism involves hundreds of bioactive compounds, and the pharmaceutical assault on nutritional status extends well beyond the usual suspects. Medications can deplete amino acids, deplete or impair the synthesis of endogenous antioxidants like glutathione, drain cofactors that don’t even have an RDA, and interfere with trace minerals that most doctors never test.
This companion guide covers 30 nutrients that are at risk from common medications but rarely appear in standard drug-nutrient interaction references. For each nutrient, we identify the depleting drug classes, explain the mechanism, rate the evidence, and provide practical repletion guidance.
This article is educational information, not medical advice. Always discuss supplementation with your prescribing physician or pharmacist before starting any new supplement, especially if you take prescription medications.
Endogenous Antioxidants and Detoxification Molecules
These are compounds your body normally manufactures, but medication use can impair their production or accelerate their consumption.
Glutathione
Glutathione (GSH) is the body’s most abundant intracellular antioxidant and the primary molecule responsible for phase II detoxification in the liver. Every medication metabolized by the liver consumes glutathione to some degree — the liver uses glutathione conjugation as one of its primary mechanisms for rendering drug metabolites water-soluble and excretable.
The most dramatic example is acetaminophen (Tylenol/paracetamol). At therapeutic doses, about 5–10% of acetaminophen is metabolized through the CYP2E1 pathway to NAPQI (N-acetyl-p-benzoquinone imine), a highly reactive toxic metabolite that is normally immediately neutralized by glutathione conjugation. At high doses or with chronic use, NAPQI production overwhelms glutathione supply, leading to the hepatocellular necrosis that makes acetaminophen overdose the leading cause of acute liver failure in the Western world [1][2]. This is why N-acetylcysteine (NAC) — a glutathione precursor — is the antidote for acetaminophen overdose.
But acetaminophen isn’t the only glutathione-depleting medication. Any drug heavily metabolized by CYP enzymes increases glutathione demand, and chronic use of multiple medications (polypharmacy) creates cumulative glutathione drain.
| Drug Class | Glutathione Impact | Evidence | Mechanism |
|---|---|---|---|
| Acetaminophen (chronic use) | Severe depletion | Strong ●●● | NAPQI conjugation consumes GSH directly |
| Alcohol (with any hepatotoxic drug) | Severe depletion | Strong ●●● | CYP2E1 induction + direct GSH consumption |
| Chemotherapy agents (cisplatin, doxorubicin) | Severe depletion | Strong ●●● | Massive oxidative stress + direct GSH conjugation |
| Antiretrovirals (AZT, d4T) | Moderate depletion | Moderate ●● | Mitochondrial oxidative stress |
| NSAIDs (chronic use) | Mild-moderate depletion | Moderate ●● | Hepatic CYP metabolism + GI oxidative stress |
| Antiepileptics (valproic acid, phenytoin) | Moderate depletion | Moderate ●● | Hepatic metabolism + oxidative stress |
Repletion protocol: NAC (N-acetylcysteine) 600–1,200 mg/day is the most effective oral glutathione precursor. Liposomal glutathione 250–500 mg/day is an alternative for direct supplementation, though oral bioavailability of glutathione itself is debated. Whey protein (undenatured) provides cysteine for glutathione synthesis. Glycine 3–5 g/day provides the other limiting amino acid for GSH synthesis.
N-Acetylcysteine (NAC)
While NAC is technically a supplement rather than a body-produced nutrient, it deserves separate discussion because it represents the cysteine pool — the rate-limiting precursor for glutathione synthesis. When medications deplete glutathione, cysteine reserves drop in parallel. The clinical significance of NAC goes beyond glutathione replenishment: it also serves as a direct antioxidant, supports mucus thinning in respiratory conditions, and modulates glutamate neurotransmission.
Akakpo et al. (2022) compared NAC with 4-methylpyrazole as antidotes for acetaminophen overdose, confirming NAC’s role as the gold-standard intervention for drug-induced glutathione depletion [3]. Beyond acute overdose, chronic low-dose acetaminophen use in the elderly — common for arthritis and chronic pain — creates a persistent low-grade glutathione deficit that NAC supplementation can address.
Repletion protocol: NAC 600–1,200 mg/day, taken on an empty stomach for best absorption. Can cause GI upset; start at 600 mg and increase gradually.
Coenzyme A (CoA)
Coenzyme A is built from pantothenic acid (vitamin B5), cysteine, and ATP. It’s essential for the citric acid cycle, fatty acid oxidation, and acetylcholine synthesis. Medications that consume CoA or impair its synthesis affect energy metabolism at a fundamental level.
Statins inhibit HMG-CoA reductase — the enzyme that converts HMG-CoA to mevalonate in cholesterol synthesis. While statins don’t directly deplete CoA, they shift the HMG-CoA/CoA ratio, and the mevalonate pathway blockade has downstream effects on CoA-dependent processes. The more clinically significant CoA depletion comes from valproic acid, which sequesters CoA through conjugation reactions, contributing to the drug’s hepatotoxicity and mitochondrial dysfunction.
Repletion protocol: Pantothenic acid (vitamin B5) 500–1,000 mg/day provides the primary substrate. Pantethine 300–600 mg/day (the active form of B5) is more directly bioavailable for CoA synthesis.
L-Carnitine and Related Compounds
L-Carnitine
L-carnitine shuttles long-chain fatty acids across the mitochondrial membrane for beta-oxidation — without it, cells cannot burn fat for energy. Carnitine deficiency manifests as muscle weakness, fatigue, cardiomyopathy, and in severe cases, hepatic encephalopathy.
Valproic acid is the most thoroughly documented carnitine-depleting medication. Schiavo et al. (2023) developed a quantitative systems pharmacology model characterizing how valproic acid causes hyperammonemia through carnitine depletion, demonstrating that L-carnitine supplementation directly addresses this mechanism [4]. Stadler et al. (1999) documented impaired carnitine reabsorption efficiency in humans on long-term valproic acid [5].
Other carnitine-depleting medications include:
| Drug Class | Carnitine Impact | Evidence | Mechanism |
|---|---|---|---|
| Valproic acid | Severe depletion | Strong ●●● | Inhibits biosynthesis + forms valproylcarnitine esters → renal excretion |
| Pivalate-containing antibiotics (pivampicillin, pivmecillinam) | Severe depletion | Strong ●●● | Pivaloyl group conjugates with carnitine → pivaloylcarnitine excreted in urine |
| Zidovudine (AZT) | Moderate depletion | Moderate ●● | Mitochondrial DNA polymerase-γ inhibition → impaired mitochondrial function |
| Cisplatin | Moderate depletion | Moderate ●● | Renal tubular damage → carnitine wasting |
| Isotretinoin (Accutane) | Mild depletion | Weak ● | Altered lipid metabolism |
Repletion protocol: L-carnitine 500–2,000 mg/day in divided doses. Acetyl-L-carnitine (ALCAR) 500–1,000 mg/day preferred for neurological symptoms (crosses the blood-brain barrier). For valproic acid users: L-carnitine supplementation is considered standard of care in pediatric neurology, recommended at 50–100 mg/kg/day (max 3 g/day) for children.
Acetyl-L-Carnitine (ALCAR)
While ALCAR is a form of carnitine, it has distinct neurological significance because it crosses the blood-brain barrier and participates in acetylcholine synthesis. Medications that impair mitochondrial function in the brain — including certain antiretrovirals, chemotherapy agents, and antiepileptics — disproportionately affect brain carnitine/ALCAR pools. Clinical symptoms include cognitive fog, neuropathy, and depression that may be partially attributed to the underlying condition rather than the medication-induced depletion.
Repletion protocol: ALCAR 500–1,500 mg/day, typically in morning dosing to avoid sleep disruption.
Amino Acids and Amino Acid Derivatives
Taurine
Taurine is a conditionally essential amino acid that plays critical roles in bile acid conjugation, cell membrane stabilization, calcium signaling in cardiac muscle, and antioxidant defense. It’s concentrated in the heart, brain, and retina.
Chemotherapy agents — particularly cisplatin and its nephrotoxic effects — deplete taurine through renal wasting. Loop diuretics (furosemide, bumetanide) increase renal taurine excretion alongside other osmolytes. Beta-blockers have been associated with reduced taurine levels in some studies, though the mechanism is less clear — possibly related to altered cardiac taurine uptake.
| Drug Class | Taurine Impact | Evidence | Mechanism |
|---|---|---|---|
| Loop diuretics (furosemide) | Moderate depletion | Moderate ●● | Increased renal excretion of osmolytes including taurine |
| Chemotherapy (cisplatin) | Moderate depletion | Moderate ●● | Nephrotoxicity → tubular taurine wasting |
| Beta-blockers | Mild depletion | Weak ● | Altered cardiac taurine uptake (mechanism unclear) |
| Metformin (long-term) | Mild depletion | Weak ● | Altered amino acid metabolism; increased renal clearance |
Repletion protocol: Taurine 500–2,000 mg/day. Well-tolerated with minimal side effects. Cardiac patients on diuretics may particularly benefit from taurine’s cardioprotective properties.
Choline
Choline is an essential nutrient (most adults don’t meet the adequate intake even without medication interference) that serves as the precursor to acetylcholine (the primary neurotransmitter for memory and muscle control) and phosphatidylcholine (a major membrane phospholipid and component of bile).
Methotrexate — used for cancer, rheumatoid arthritis, and psoriasis — impairs folate metabolism, which is intimately connected to choline metabolism. When folate is depleted, the body compensates by using choline as an alternative methyl donor, depleting choline reserves. This folate-choline metabolic crosstalk means that any medication depleting folate (methotrexate, phenytoin, trimethoprim, sulfasalazine) indirectly depletes choline as well.
Anticholinergic medications — a broad class including diphenhydramine, oxybutynin, tricyclic antidepressants, and many others — don’t deplete choline per se, but they block its primary neurotransmitter product (acetylcholine) at the receptor level, creating a functional choline deficit.
| Drug Class | Choline Impact | Evidence | Mechanism |
|---|---|---|---|
| Methotrexate | Moderate depletion | Moderate ●● | Folate depletion → compensatory choline use as methyl donor |
| Phenytoin | Mild-moderate depletion | Moderate ●● | Same folate-choline crosstalk |
| Anticholinergics (diphenhydramine, etc.) | Functional deficit | Strong ●●● | Blocks acetylcholine receptors; doesn’t deplete stores directly |
| Oral contraceptives | Mild depletion | Weak ● | Estrogen alters choline metabolism and distribution |
Repletion protocol: Choline (as CDP-choline/citicoline) 250–500 mg/day, or phosphatidylcholine 1,200–2,400 mg/day. Alpha-GPC 300–600 mg/day for more direct acetylcholine precursor support. Egg yolks (147 mg choline per yolk) remain the best dietary source.
Inositol (Myo-inositol)
Inositol functions as a secondary messenger in insulin signaling, serotonin receptor sensitivity, and phospholipid metabolism. It’s technically classified as a B-vitamin-like compound, though the body synthesizes it from glucose.
Lithium — the mood stabilizer — is the most well-documented inositol-depleting medication. Lithium inhibits inositol monophosphatase (IMPase), reducing free inositol availability. This inositol depletion is actually believed to be part of lithium’s therapeutic mechanism in bipolar disorder — the “inositol depletion hypothesis” suggests that dampening inositol-dependent signaling reduces the manic episodes. However, it also means that lithium-treated patients may have systemically low inositol, with consequences for insulin signaling, fertility, and other inositol-dependent processes.
Valproic acid also reduces brain inositol levels, though through a different mechanism (inhibiting inositol biosynthesis from glucose-6-phosphate). Alesi et al. (2022) reviewed the role of inositol in polycystic ovary syndrome, noting that inositol supplementation improves insulin sensitivity — a finding relevant to patients on antipsychotics or mood stabilizers that impair insulin signaling [6].
| Drug Class | Inositol Impact | Evidence | Mechanism |
|---|---|---|---|
| Lithium | Significant depletion | Strong ●●● | Inhibits inositol monophosphatase (IMPase) |
| Valproic acid | Moderate depletion | Moderate ●● | Inhibits inositol biosynthesis from glucose-6-phosphate |
| Carbamazepine | Mild depletion | Weak ● | Reduces inositol levels in brain (mechanism not fully characterized) |
| SSRIs (long-term) | Altered metabolism | Weak ● | Serotonin signaling modifies inositol phospholipid turnover |
Repletion protocol: Myo-inositol 2–4 g/day for insulin sensitization or general support. For bipolar patients on lithium: inositol supplementation is controversial because depleting inositol may be part of how lithium works — discuss with psychiatrist before supplementing.
Alpha-Lipoic Acid (ALA)
Alpha-lipoic acid is a unique antioxidant that works in both water-soluble and fat-soluble environments, regenerates other antioxidants (vitamins C and E, glutathione), and serves as a cofactor for mitochondrial enzyme complexes involved in energy production.
ALA is not directly “depleted” by medications in the same way that minerals are depleted through chelation or renal wasting. Instead, medications that increase oxidative stress — chemotherapy, chronic NSAID use, acetaminophen, antiretrovirals — accelerate the consumption of ALA as it’s used to quench free radicals and regenerate glutathione. The net result is a functional ALA deficit even though no specific renal or absorptive mechanism is impaired.
Singh and Jialal (2008) reviewed alpha-lipoic acid supplementation in diabetes, noting its established role in managing diabetic neuropathy — a condition that overlaps significantly with medication-induced neuropathy from drugs like metformin, statins, and certain chemotherapy agents [7].
Repletion protocol: R-alpha-lipoic acid 300–600 mg/day (the R-enantiomer is the biologically active form). Stabilized R-ALA or Na-R-ALA preferred for bioavailability. Take on an empty stomach, 30 minutes before meals. May lower blood sugar — monitor if diabetic.
Trace Minerals
Selenium
Selenium is essential for selenoprotein production — including glutathione peroxidase (the enzyme that uses glutathione to neutralize peroxides) and thyroid deiodinases (the enzymes that convert T4 to active T3). Selenium deficiency impairs both antioxidant defense and thyroid function.
Medications that increase selenium demand or deplete it include:
| Drug Class | Selenium Impact | Evidence | Mechanism |
|---|---|---|---|
| Valproic acid | Moderate depletion | Moderate ●● | Increases oxidative stress → increased selenoprotein consumption |
| Corticosteroids (chronic) | Mild depletion | Moderate ●● | Altered selenium distribution and increased urinary excretion |
| Chemotherapy (cisplatin) | Moderate depletion | Moderate ●● | Nephrotoxicity + massive oxidative stress |
| PPIs (long-term) | Mild depletion | Weak ● | Reduced gastric acid impairs selenium absorption from food |
Repletion protocol: Selenium (as selenomethionine or selenium yeast) 100–200 mcg/day. Do not exceed 400 mcg/day — selenium has a narrow therapeutic window and toxicity (selenosis) occurs at doses not far above the therapeutic range.
Chromium
Chromium potentiates insulin signaling by enhancing insulin receptor phosphorylation. While the essential role of chromium has been debated, medications that impair insulin sensitivity — particularly second-generation antipsychotics and corticosteroids — increase chromium demand.
Corticosteroids (prednisone, dexamethasone) are the most significant chromium-depleting drugs: they cause insulin resistance through multiple mechanisms, and the resulting hyperglycemia increases urinary chromium excretion by 2–3 fold. Patients on long-term corticosteroids who develop steroid-induced diabetes may particularly benefit from chromium support.
| Drug Class | Chromium Impact | Evidence | Mechanism |
|---|---|---|---|
| Corticosteroids (chronic) | Moderate depletion | Moderate ●● | Insulin resistance → hyperglycemia → increased urinary chromium loss |
| Second-generation antipsychotics | Increased demand | Weak ● | Metabolic syndrome → increased chromium utilization |
| Loop diuretics | Mild depletion | Weak ● | Increased urinary excretion |
Repletion protocol: Chromium picolinate 200–1,000 mcg/day. Chromium GTF (glucose tolerance factor) is an alternative form. Effects on blood sugar are modest but consistent in insulin-resistant populations. Monitor blood glucose if diabetic.
Manganese
Manganese is a cofactor for superoxide dismutase (MnSOD, the primary mitochondrial antioxidant enzyme), arginase, and pyruvate carboxylase. Manganese deficiency is rare in the general population but may be clinically relevant in patients on medications that increase its excretion or impair its absorption.
Antacids and PPIs reduce gastric acid, which impairs manganese absorption. Chronic use of chelating antibiotics (tetracyclines, fluoroquinolones) may bind manganese alongside other divalent cations, though the evidence for clinically significant manganese depletion from these drugs is limited.
Repletion protocol: Manganese 2–5 mg/day. Do not exceed 11 mg/day. Manganese toxicity (manganism) is a serious neurotoxic condition — supplementation should be cautious and only when deficiency is suspected.
Molybdenum
Molybdenum is a cofactor for sulfite oxidase, xanthine oxidase, and aldehyde oxidase — enzymes involved in sulfur amino acid metabolism and purine degradation. Molybdenum deficiency is extremely rare but can theoretically occur in patients on total parenteral nutrition (TPN) without molybdenum supplementation, or in patients on chronic high-dose antacids that impair trace mineral absorption.
Repletion protocol: Molybdenum 75–250 mcg/day if deficiency is suspected. Most multivitamins contain adequate amounts.
Iodine
Iodine is essential for thyroid hormone synthesis. While amiodarone causes iodine excess rather than deficiency (see our Part 2 companion article), other medications can impair iodine utilization:
Lithium competes with iodine uptake at the thyroid gland and inhibits thyroid peroxidase — the enzyme that incorporates iodine into thyroglobulin. The result is impaired thyroid hormone synthesis despite potentially adequate iodine intake.
Perchlorate (rarely used as a medication but present as an environmental contaminant that can affect patients on thyroid medications) competitively inhibits the sodium-iodide symporter (NIS), reducing iodine uptake into the thyroid.
Repletion protocol: Iodine supplementation in patients on lithium or other thyroid-affecting medications should be guided by thyroid function tests and supervised by an endocrinologist. Blind iodine supplementation in these patients can worsen thyroid dysfunction.
Boron
Boron influences calcium and magnesium metabolism, vitamin D utilization, and estrogen activity. Medications that deplete calcium and magnesium (loop diuretics, corticosteroids, PPIs) may indirectly increase boron demand because boron is required for optimal calcium metabolism.
Repletion protocol: Boron 3–6 mg/day. Generally safe and well-tolerated.
Silicon
Silicon (as orthosilicic acid) contributes to collagen cross-linking and bone mineralization. Medications that impair bone health — corticosteroids, aromatase inhibitors, long-term PPIs, anticonvulsants — may increase the relevance of silicon status for maintaining skeletal integrity.
Repletion protocol: Silicon (as orthosilicic acid or stabilized choline-stabilized orthosilicic acid) 5–10 mg/day.
Vanadium
Vanadium has insulin-mimetic properties — vanadium compounds can activate the insulin receptor and promote glucose uptake independent of insulin signaling. While not traditionally considered an essential mineral, it may be particularly relevant for patients on medications that impair insulin sensitivity (antipsychotics, corticosteroids, protease inhibitors).
Repletion protocol: Vanadium (as vanadyl sulfate or bis(maltolato)oxovanadium) 10–50 mcg/day. Evidence for supplementation is preliminary. High doses can cause GI toxicity.
The Functional Depletion Concept
Many of the nutrients in this article aren’t depleted through the classical mechanisms of impaired absorption or increased excretion. Instead, they’re functionally depleted — medication use increases the body’s demand for these compounds faster than diet or synthesis can supply them.
This distinction matters clinically because:
- Standard blood tests won’t detect functional depletion. Serum glutathione, taurine, or carnitine levels may appear normal even when cellular pools are depleted.
- The symptoms overlap with medication side effects. Fatigue from carnitine depletion looks identical to fatigue from the medication itself. Cognitive fog from choline functional deficit resembles the cognitive effects of anticholinergic medications.
- Supplementation often improves symptoms attributed to the medication. This is the strongest indirect evidence that functional depletion is occurring — when addressing the nutrient deficit alleviates symptoms that were assumed to be drug side effects.
The practical takeaway: if you’re experiencing side effects from medication that don’t improve with dose adjustment, a comprehensive nutritional evaluation — including the nutrients in this article, not just the standard panel — may reveal correctable deficiencies.
Complete Expanded Nutrient Summary Table
| Nutrient | Primary Depleting Drug Classes | Evidence Level | Key Repletion Form | Typical Dose Range |
|---|---|---|---|---|
| Glutathione | Acetaminophen, chemotherapy, antiretrovirals | Strong ●●● | NAC or liposomal glutathione | NAC 600–1,200 mg/day |
| NAC (cysteine pool) | Same as glutathione depletors | Strong ●●● | NAC | 600–1,200 mg/day |
| Coenzyme A | Valproic acid, statins (indirect) | Moderate ●● | Pantothenic acid / Pantethine | B5 500–1,000 mg/day |
| L-Carnitine | Valproic acid, pivalate antibiotics, cisplatin | Strong ●●● | L-Carnitine or ALCAR | 500–2,000 mg/day |
| Acetyl-L-Carnitine | Antiretrovirals, antiepileptics, chemotherapy | Moderate ●● | ALCAR | 500–1,500 mg/day |
| Taurine | Loop diuretics, cisplatin | Moderate ●● | Taurine | 500–2,000 mg/day |
| Choline | Methotrexate, phenytoin, anticholinergics | Moderate ●● | CDP-choline or Alpha-GPC | 250–600 mg/day |
| Inositol | Lithium, valproic acid | Strong ●●● | Myo-inositol | 2–4 g/day |
| Alpha-Lipoic Acid | Chemotherapy, chronic NSAIDs, acetaminophen | Moderate ●● | R-Alpha-Lipoic Acid | 300–600 mg/day |
| Selenium | Valproic acid, corticosteroids, cisplatin | Moderate ●● | Selenomethionine | 100–200 mcg/day |
| Chromium | Corticosteroids, antipsychotics | Moderate ●● | Chromium picolinate | 200–1,000 mcg/day |
| Manganese | PPIs, antacids, chelating antibiotics | Weak ● | Manganese (glycinate or citrate) | 2–5 mg/day |
| Molybdenum | TPN without supplementation, chronic antacids | Weak ● | Molybdenum (glycinate) | 75–250 mcg/day |
| Iodine | Lithium (impairs utilization) | Strong ●●● | Iodine (supervised only) | Per endocrinologist |
| Boron | Diuretics, corticosteroids (indirect) | Weak ● | Boron (glycinate) | 3–6 mg/day |
| Silicon | Bone-depleting drugs (corticosteroids, PPIs) | Weak ● | Orthosilicic acid | 5–10 mg/day |
| Vanadium | Antipsychotics, corticosteroids (insulin resistance) | Weak ● | Vanadyl sulfate | 10–50 mcg/day |
| Glycine | Acetaminophen (GSH conjugation) | Moderate ●● | Glycine powder | 3–5 g/day |
| Cysteine | Any hepatotoxic drug (GSH precursor demand) | Moderate ●● | NAC (cysteine donor) | 600–1,200 mg/day |
| Tyrosine | MAOIs, methyldopa, carbidopa/levodopa | Moderate ●● | L-Tyrosine | 500–2,000 mg/day (with medical guidance) |
| Tryptophan | SSRIs (increased demand), oral contraceptives | Moderate ●● | L-Tryptophan | 500–1,000 mg/day (not with SSRIs) |
| Glutamine | Chemotherapy, corticosteroids | Moderate ●● | L-Glutamine | 5–15 g/day |
| Methionine | Methotrexate (methylation demand) | Weak ● | SAMe or methionine | SAMe 400–800 mg/day |
| CoQ10 | Statins, beta-blockers, some antipsychotics | Strong ●●● | Ubiquinol | 100–300 mg/day |
| Melatonin | Beta-blockers, NSAIDs, benzodiazepines | Moderate ●● | Melatonin | 0.5–3 mg at bedtime |
| Vitamin K2 | Warfarin (antagonist), antibiotics (gut flora) | Moderate ●● | MK-7 (consult if on warfarin) | 100–200 mcg/day (NOT with warfarin) |
| Phosphatidylserine | Corticosteroids (cortisol excess) | Weak ● | Phosphatidylserine | 100–300 mg/day |
| DHA/EPA (Omega-3) | Statins (altered lipid metabolism) | Weak ● | Fish oil or algae oil | 1–2 g combined EPA/DHA daily |
Frequently Asked Questions
Are these lesser-known nutrient depletions as clinically significant as the well-known ones (B12, magnesium, CoQ10)?
Some are, some aren’t. Carnitine depletion from valproic acid is clinically significant enough that L-carnitine supplementation is standard of care in pediatric neurology. Glutathione depletion from acetaminophen is literally life-threatening in overdose. On the other hand, vanadium or silicon depletion is theoretical with limited clinical evidence. The evidence ratings in our tables reflect this spectrum — focus your attention on the Strong (●●●) and Moderate (●●) rated interactions, and treat Weak (●) entries as areas of awareness rather than action.
My doctor hasn’t heard of most of these nutrients. Should I be worried?
Most medical education focuses on macronutrients and the vitamins/minerals that have established deficiency diseases (scurvy, rickets, beriberi, pellagra). Nutrients like taurine, carnitine, choline, and glutathione are typically covered in biochemistry courses but not in clinical nutrition training. This doesn’t mean the depletions aren’t real — it means the clinical awareness hasn’t caught up with the biochemistry. An integrative medicine practitioner or clinical nutritionist may be better equipped to evaluate these specific nutrients.
Can I just take a comprehensive supplement stack to cover all potential depletions?
This approach is tempting but problematic for several reasons. First, some nutrients on this list (selenium, manganese, iodine) have narrow therapeutic windows where overdose is dangerous. Second, some supplements interact with the medications causing the depletion — supplementing inositol while on lithium may counteract the drug’s therapeutic mechanism. Third, the cost of supplementing 30 nutrients unnecessarily is substantial. The better approach: identify which medications you take, cross-reference with the depletion tables, and target only the nutrients relevant to your specific medication regimen.
How does this relate to the “main” Medication-Nutrient Depletion Database?
Our Complete Medication-Nutrient Depletion Database covers the top 60 medication-nutrient interactions focusing on well-established depletions of standard vitamins and minerals (B12, D, magnesium, calcium, iron, zinc, CoQ10, folate, potassium, etc.). This article expands the nutrient side — covering 30 additional nutrients that the standard database doesn’t address. Our Part 2 article expands the medication side — covering 30+ additional drugs beyond the top 60. Together, the three articles provide the most comprehensive medication-nutrient depletion resource available.
Is there a test I can ask my doctor to run for these nutrients?
Some of these nutrients have available lab tests: carnitine (total and free), selenium (serum), chromium (serum, though not widely available), taurine (plasma amino acid panel), choline (not routinely available), glutathione (erythrocyte GSH — specialized labs only). For many, there is no standard clinical test, and the best diagnostic approach is a therapeutic trial: supplement the suspected deficiency for 4–8 weeks and evaluate whether symptoms improve. If they do, continue; if not, the depletion likely isn’t the primary issue.
Sources
- Ramachandran A, Akakpo JY, Curry SC, Rumack BH, Jaeschke H. Clinically relevant therapeutic approaches against acetaminophen hepatotoxicity and acute liver failure. Biochemical Pharmacology. 2024;220:115963. PMID: 38346541
- Mantle D, Turton N, Hargreaves IP. Depletion and Supplementation of Coenzyme Q10 in Secondary Deficiency Disorders. Frontiers in Bioscience (Landmark Edition). 2022;27(12):322. PMID: 36624950
- Akakpo JY, Ramachandran A, Curry SC, Rumack BH, Jaeschke H. Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose. Archives of Toxicology. 2022;96(2):453-465. PMID: 34978586
- Schiavo A, Maldonado C, Vázquez M, et al. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. European Journal of Pharmaceutical Sciences. 2023;183:106393. PMID: 36740101
- Stadler DD, Bale JF Jr, Chenard CA, Rebouche CJ. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. Metabolism. 1999;48(1):74-79. PMID: 9920148
- Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Advances in Nutrition. 2022;13(4):1243-1266. PMID: 34970669
- Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutrition Reviews. 2008;66(11):646-657. PMID: 19019027
- Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. BioFactors. 2003;18(1-4):101-111. PMID: 14695925
- Eckard AR, McComsey GA. Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Current HIV/AIDS Reports. 2014;11(3):263-270. PMID: 24962286
- De Waele L, Van Gaal PJ, Abramowicz D. Electrolytes disturbances after kidney transplantation. Acta Clinica Belgica. 2019;74(1):48-55. PMID: 30482110
Related Articles
- The Complete Medication-Nutrient Depletion Database — The original database covering the top 60 medications
- Medication-Nutrient Depletion Matrix Part 2: Beyond the Top 60 — 30+ additional medications not in the main database
- Dangerous Supplement Interactions You Need to Know — Critical supplement-drug interaction warnings
This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease. Always consult your physician, pharmacist, or qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen. Individual responses to medications and supplements vary, and what works for one person may not be appropriate for another.
Leave a Reply